A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort

Trial Profile

A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Bendamustine (Primary) ; Alemtuzumab; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
  • Indications Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Weill Cornell Medical College
  • Most Recent Events

    • 11 Dec 2017 Planned number of patients changed from 30 to 90.
    • 11 Dec 2017 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
    • 11 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top